Table 2.
Effects of TSAV on serum enzyme activities with CCl4-induced hepatic damage in mice.
| Group | AST (IU/L) | ALT (IU/L) | ALP (IU/L) |
|---|---|---|---|
| I | 58.71a ± 17.02 | 24.10a ± 3.72 | 139.58a ± 15.53 |
| II | 1724.82d ± 478.62 | 4112.02d ± 1062.96 | 250.12c ± 14.99 |
| III | 1250.11c ± 334.93 | 2583.45c ± 426.52 | 217.23b ± 23.71 |
| IV | 1164.23c ± 259.20 | 2563.52c ± 401.25 | 194.98b ± 18.39 |
| V | 901.60b ± 231.51 | 2231.91b ± 407.22 | 151.08a ± 07.41 |
| VI | 1190.54c ± 262.20 | 2533.93c ± 446.91 | 166.78a ± 13.84 |
Group I: control; Group II: CCl4; Group III: TSAV 50 mg/kg + CCl4; Group IV: TSAV 100 mg/kg + CCl4; Group V: TSAV 200 mg/kg + CCl4; Group VI: silymarin 200 mg/kg + CCl4.
Values are given as mean ± SD (n = 10 mice/group); means with different alphabets differ significantly at P < 0.05 level.